Filter Results:
- Full text PDF available (17)
Publication Year
1973
2015
- This year (0)
- Last 5 years (2)
- Last 10 years (12)
Publication Type
Co-author
Journals and Conferences
Learn More
- Suzanne A W Fuqua, Christoph Wiltschke, +8 authors D Craig Allred
- Cancer research
- 2000
The best current model of breast cancer evolution suggests that most cancers arise from certain premalignant lesions. We have identified a common (34%) somatic mutation in the estrogen receptor… (More)
- Donald Craig Allred, S. Mohsin, Suzanne A W Fuqua
- Endocrine-related cancer
- 2001
Most human invasive breast cancers (IBCs) appear to develop over long periods of time from certain pre-existing benign lesions. Of the many types of benign lesions in the human breast, only a few… (More)
- M. Carolina Gutiérrez, Simone I Detre, +6 authors Mitch Dowsett
- Journal of clinical oncology : official journal…
- 2005
PURPOSE
To evaluate growth factor receptor cross talk with the estrogen receptor (ER) in paired clinical breast cancer specimens and in a xenograft model before tamoxifen and at tumor progression as… (More)
- Suzanne A. W. Fuqua, Rachel Schiff, +5 authors D. Craig. Allred
- Cancer research
- 2003
The recent discovery of a second estrogen receptor (ER), designated ERbeta, raises pressing questions about its role in estrogen regulation of human breast cancer cells and its significance for the… (More)
- D. Craig. Allred, Yun Wu, +7 authors Daniel J. Medina
- Clinical cancer research : an official journal of…
- 2008
PURPOSE
Human invasive breast cancers (IBC) show enormous histologic and biological diversity. This study comprehensively evaluated diversity in ductal carcinoma in situ (DCIS), the immediate… (More)
- Suleiman Alfred Massarweh, Caroline K Osborne, +5 authors Rachel Schiff
- Cancer research
- 2006
HER-2/neu in breast cancer is associated with tamoxifen resistance, but little data exist on its interaction with estrogen deprivation or fulvestrant. Here, we used an in vivo xenograft model of… (More)
- David J. Dabbs, Molly E. Klein, S. Mohsin, Raymond R. Tubbs, Yongli Shuai, Rohit Bhargava
- Journal of clinical oncology : official journal…
- 2011
PURPOSE
HER2 (ERBB2) status is an important prognostic and predictive marker in breast carcinoma. In recent years, Genomic Health (GHI), purveyors of the Oncotype DX test, has been separately… (More)
- Sangjun Lee, S. Mohsin, Sufeng Mao, Susan G. Hilsenbeck, Daniel J. Medina, Donald Craig Allred
- Breast Cancer Research
- 2005
The hyperplastic enlarged lobular unit (HELU) is a common alteration in adult female human breast and is the earliest histologically identifiable lesion with premalignant potential. Growth and… (More)
- S. Mohsin, Heidi L. Weiss, +9 authors Jenny C. Chang
- Nature Clinical Practice Oncology
- 2005
PURPOSE
Greater understanding of the cellular response in trastuzumab-treated patients will provide insight into the clinical management of patients.
PATIENTS AND METHODS
We performed a neoadjuvant… (More)
- Richard Reed Love, Nguyen Ba Duc, +4 authors D. Craig. Allred
- Journal of clinical oncology : official journal…
- 2003
PURPOSE
Studies evaluating the relationship of HER-2/neu breast tumor status and response to adjuvant endocrine therapy have reached conflicting conclusions about resistance of HER-2/neu-positive… (More)